First Eagle Investment Management LLC raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 40.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 212,612 shares of the company’s stock after buying an additional 60,912 shares during the period. First Eagle Investment Management LLC’s holdings in Progyny were worth $5,460,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares in the last quarter. Amundi increased its holdings in Progyny by 103.8% in the 1st quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after purchasing an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares in the last quarter. Invesco Ltd. raised its position in Progyny by 37.4% in the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the period. Finally, Walleye Capital LLC lifted its stake in shares of Progyny by 6.9% during the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after purchasing an additional 780 shares in the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. Truist Financial upped their target price on Progyny from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group reduced their price target on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. Citizens Jmp upped their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, BTIG Research dropped their price objective on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and a consensus price target of $28.18.
Progyny Stock Performance
NASDAQ:PGNY opened at $23.51 on Thursday. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 30.53, a price-to-earnings-growth ratio of 1.25 and a beta of 0.91. Progyny, Inc. has a one year low of $16.10 and a one year high of $28.75. The business’s 50-day simple moving average is $18.16 and its 200 day simple moving average is $21.80.
Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.47 million. During the same quarter last year, the firm earned $0.17 EPS. Progyny’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities research analysts predict that Progyny, Inc. will post 1.12 EPS for the current year.
Insider Buying and Selling at Progyny
In other news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 7,455 shares of company stock worth $129,515 over the last three months. 9.90% of the stock is currently owned by company insiders.
Progyny Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Featured Articles
- Five stocks we like better than Progyny
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
